Reynders Mc Veigh Capital Management, LLC Bluebird Bio, Inc. Transaction History

Reynders Mc Veigh Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$26.16 - $63.5 $93,652 - $227,330	-3,580 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$46.96 - $61.67 $22,306 - $29,293	-475 Reduced 11.71%	3,580 $314,000
Q3 2019 Nov 08, 2019	SELL	$59.47 - $93.1 $56,496 - $88,445	-950 Reduced 18.98%	4,055 $372,000
Q2 2019 Aug 06, 2019	BUY	$75.84 - $105.21 $3,792 - $5,260	50 Added 1.01%	5,005 $637,000
Q1 2019 May 10, 2019	SELL	$64.44 - $104.11 $8,055 - $13,013	-125 Reduced 2.46%	4,955 $780,000
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $101,652 - $160,407	-1,720 Reduced 25.29%	5,080 $504,000
Q2 2018 Aug 09, 2018	BUY	$99.64 - $127.59 $24,910 - $31,897	250 Added 3.82%	6,800 $1.07 Million
Q1 2018 Jul 26, 2018	BUY	$105.8 - $150.94 $574,705 - $819,906	5,432 Added 485.87%	6,550 $1.12 Million
Q1 2018 May 03, 2018	SELL	$105.8 - $150.94 $573,118 - $817,641	-5,417 Reduced 82.89%	1,118 $6.55 Million
Q3 2017 Nov 09, 2017	SELL	$57.74 - $91.42 $57,740 - $91,420	-1,000 Reduced 13.27%	6,535 $898,000
Q2 2017 Aug 14, 2017	BUY	N/A	7,535	7,535 $792,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.